Nothing Special   »   [go: up one dir, main page]

AU2001237414A1 - Cancer treatment and prognosis - Google Patents

Cancer treatment and prognosis

Info

Publication number
AU2001237414A1
AU2001237414A1 AU2001237414A AU3741401A AU2001237414A1 AU 2001237414 A1 AU2001237414 A1 AU 2001237414A1 AU 2001237414 A AU2001237414 A AU 2001237414A AU 3741401 A AU3741401 A AU 3741401A AU 2001237414 A1 AU2001237414 A1 AU 2001237414A1
Authority
AU
Australia
Prior art keywords
prognosis
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001237414A
Inventor
Jan Ake Gustafsson
Anders Strom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Pharma AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004568A external-priority patent/GB0004568D0/en
Priority claimed from GB0018587A external-priority patent/GB0018587D0/en
Priority claimed from GB0021508A external-priority patent/GB0021508D0/en
Application filed by Karo Bio AB filed Critical Karo Bio AB
Publication of AU2001237414A1 publication Critical patent/AU2001237414A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001237414A 2000-02-25 2001-02-26 Cancer treatment and prognosis Abandoned AU2001237414A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0004568A GB0004568D0 (en) 2000-02-25 2000-02-25 Cancer treatment and prognosis
GB0004568 2000-02-25
GB0018587 2000-07-28
GB0018587A GB0018587D0 (en) 2000-07-28 2000-07-28 Cancer treatment and prognosis
GB0021508 2000-09-01
GB0021508A GB0021508D0 (en) 2000-09-01 2000-09-01 Cancer treatment and prognosis
PCT/EP2001/002171 WO2001062792A2 (en) 2000-02-25 2001-02-26 Cancer treatment and prognosis involving hes-1 protein

Publications (1)

Publication Number Publication Date
AU2001237414A1 true AU2001237414A1 (en) 2001-09-03

Family

ID=27255559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001237414A Abandoned AU2001237414A1 (en) 2000-02-25 2001-02-26 Cancer treatment and prognosis

Country Status (4)

Country Link
US (1) US20030144194A1 (en)
EP (1) EP1257286A2 (en)
AU (1) AU2001237414A1 (en)
WO (1) WO2001062792A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000509644A (en) 1996-05-03 2000-08-02 ダグラス,パトリック,ジョセフ Self-propelled material processing equipment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3885999A (en) * 1998-05-05 1999-11-23 Incyte Pharmaceuticals, Inc. Human transcriptional regulator molecules

Also Published As

Publication number Publication date
WO2001062792A3 (en) 2002-04-04
EP1257286A2 (en) 2002-11-20
US20030144194A1 (en) 2003-07-31
WO2001062792A2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
AU2002219472A1 (en) Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2002223827A1 (en) Well treatment
AU2001253126A1 (en) (+) naloxone and epinephrine combination therapy
AU2001249626A1 (en) Cathepsin inhibitors in cancer treatment
AU2002319338A1 (en) Cancer specific oligosaccharide sequences and use thereof
AU1465801A (en) Methods for cancer prognosis and diagnosis
AUPQ923100A0 (en) Treatment of prostate cancer
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU2002340251A1 (en) Use of mx gtpases in the prognosis and treatment of cancer
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001257325A1 (en) Cancer treatment
GB0026015D0 (en) Cancer treatment
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU2002256556A1 (en) Sea-trosy and related methods
AU2002305138A1 (en) Methods and materials for cancer treatment
AU2001237414A1 (en) Cancer treatment and prognosis
AU5632500A (en) Cancer associated antigens and uses therefor
AU2001297571A1 (en) Detection and treatment of prostate cancer
AU5097099A (en) Methods and compositions for cancer treatment
AU2001288940A1 (en) Gene and sequence variation associated with cancer
AU2001289127A1 (en) Tumor treatment
AU2001257168A1 (en) Cancer treatment